

Bilag 2 / Schedule 2 – Information on management positions

Peter Høngaard Andersen

Chairman of the Board, Scandion Oncology A/S, and member of the Board of Directors since June 2019.

Education: Holds degrees in Chemistry, Biochemistry and Medicine.

Background: Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and Corporate Patents. Founder of Innovation Fund Denmark and Managing Director until May 2019. Chairing Innovative Medicines Initiative (IMI) from 2009 – 2014. Co-founder of Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.

Other ongoing assignments: Board member in Immunovia AB, Monsenso A/S, Venture Partner in Ysios Capital and member of the Scientific Advisory Board in Eir Ventures, CEO in Høngaard Holding ApS and CEO in Høngaard Consulting ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Jørgen Bardenfleth

Vice-Chairman of the Board, Scandion Oncology A/S, and member of the Board of Directors since 2018.

Education: MSc in Engineering from the Technical University of Denmark (DTU) and an MBA from the University of California, Los Angeles (UCLA).

Background: Professional board member since 2013, prior General Manager in high tech companies Microsoft, Intel and Hewlett-Packard 1989-2013. Board and steering committee work in Danish Science Parks, Innovationsfonden and Innovation Technology consortias.

Other ongoing assignments: Chairman of the Board in Symbion A/S, Lyngsoe Systems A/S, Dubex A/S, COBIS A/S, Lyngsoe Systems Holding A/S, Impero A/S and Mugato Licensing ApS. Vice-Chairman of the Board in BLOXHUB and Symbion Fonden. Board member in Minerva Group A/S, Bizbrains A/S, Bizbrains Holding ApS, CN3 A/S, CN3 Holding ApS, Accelerace Management A/S, Vallø Stift, Copenhagen Capacity, Ediservice ApS, swipx Holding ApS, Bimgenetic ApS, Jumpstory ApS and Konfront ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Carl Borrebaeck

Member of the Board of Directors in Scandion Oncology A/S since 2017.

Education: Holds MSc in Biochemistry and Immunology. D.Sc. in Molecular Immunology

Background: Professor Lund University. The main research interests are cancer proteomics for the generation of human therapeutic antibodies. Founded CREATE Health Translational Cancer Center 2005, focusing on clinically unmet needs. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the ResearchSweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. He received the BioTech Builder Award of the Year 2017. He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He held the position as the Vice President of Lund University, 2009-2015, responsible for innovations and industrial collaborations.

He is the founder of Immunovia AB, Senzagen AB, BioInvent International AB, Alligator Bioscience AB, PainDrainer AB.

Other ongoing assignments: Chairman of the Board in Immunovia AB, SenzaGen AB and PainDrainer AB.



Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Bo Rode Hansen

President & CEO and member of the Board of Directors in Scandion Oncology A/S since May 2020.

Education: MSc, Ph.D., MBA.

Background: Previously, President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (acquired by Roche).

Other ongoing assignments: Advisor to Novo Seeds and Abzu.

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.

Thomas Feldthus

Member of the Board of Directors in Scandion Oncology A/S since 2018.

Education: MSc in Engineering from the Technical University of Denmark (DTU), MSc in Management and Economics from the University of London, and a Fellow of the London Business School Sloan Program.

Background: Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.

Other ongoing assignments: CEO of Fertilizer Invest ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Christian Vinding Thomsen

Member of the Board of Directors in Scandion Oncology A/S since 2017.

Education: Holds a law degree (Cand.jur.) from the University of Copenhagen's Faculty of Law.

Background: Partner, attorney-at-law, Bech-Bruun Law Firm P/S. Life Science specialist (M&A and regulatory).

Other ongoing assignments: Chairman of the board in KT Stålintustri A/S and vice-chairman at Medicoindustriens Udredningspanel. Board member in Danish Life Science Law Association.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Martin Møller

Is proposed as a new member of the Board of Directors in Scandion Oncology A/S.

Education: MA in comparative literature from the University of Copenhagen.

Background: Has worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.

As a member of the Board, he will bring broad and deep experience of the international healthcare and life science industry; business strategy, including product strategy, M&A and partnering strategy for pharmaceuticals; product development knowledge; and corporate development, including global organizational development. Martin Møller will leave McKinsey & Company in the summer of 2021.



Other ongoing assignments: Board member in Immunovia AB and Mckinsey & Company Denmark P/S.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Other information: Martin Møller is a citizen of Denmark and the United States of America, born 1975.